Everolimus: novye perspektivy terapii gormonopozitivnogo raka molochnoy zhelezy


Cite item

Full Text

Abstract

References

  1. Yu H, Mohan S, Natarajan M. Radiation-triggered NF-kB activation is responsible for the angiogenic signaling pathway and neovascularization for breast cancer cell proliferation and growth. Breast Cancer (Auckl) 2012; 6: 125-35.
  2. Cheng HT, Hung WC. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. Oncol Rep 2012; 14.
  3. Harquail J, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy. An overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 2012; 1.
  4. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumor cell growth. Nature 2006; 441: 424-30.
  5. Cheng JQ, Lindsley CW, Cheng GZ et al. The Akt/PKB pathway. Molecular target for cancer drug discovery. Oncogene 2005; 24: 7482-92.
  6. Tanaka C, O'Reilly T, Kovarik JM et al. Identifying optimal biologic doses of Everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008; 26: 1596-602.
  7. O'Reilly T, Vaxelaire J, Muller M et al. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43: 71. Abstr. 359.
  8. Stoica GE, Franke TF, Wellstein A et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003; 17: 818-30.
  9. Ellard S, Gelmon KA, Chia S et al. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. J Clin Oncol 2007; 25: 141s. Abstr. 3513.
  10. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrin Metab 2007; 21: 163-72.
  11. Motzer RJ, Escudier BJ, Ouard S et al. RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC) that has progressed on VEGFr-TKI therapy. Results from a randomized, double-blind, multicenter phase III study. J Clin Oncol 2008; 26: 256s. Abstr. LBA5026.
  12. Vogelzang NJ, Bhor M, Liu Z et al. Everolimus vs temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. Clin Genitour Canc 2012; 11 (12): 1558-7673.
  13. Dong LX, Sun LL, Zhang X et al. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. Acta Pharmacol Sin 2012.
  14. Isakoff SJ, Engelman JA, Irie HY et al. Breast cancer associated PI3KCA mutations are oncogenic in mammary epithelial cells. Cancer Res 2006; 65: 10 992-11 000.
  15. Kurokawa H, Lenferink AE, Simpson JF et al. Inhibition of HER2/neu (erbB-2) and mitogenactivated protein kinases enhances tamoxifen action against HER-2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-94.
  16. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003; 9: 511-5s.
  17. Stoica GE, Franke TF, Wellstein A et al. Heregulin-b1 regulates the estrogen receptor-gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 2003; 22: 2073-87.
  18. Perez-Tenorio G, Stal O. Activation of Akt/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86: 540-5.
  19. Tokunaga E, Kataoka A, Kimura Y et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006; 42: 629-35.
  20. Yue W, Fan P, Wang J et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106: 102-10.
  21. Miller TW, Hennessy BT, Gonzalez-Angulo AM et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120: 2406-13.
  22. Santen RJ, Song RX, Zhang Z et al. Adaptive hypersensitivity to estrogen. Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005; 95: 155-65.
  23. Lane HA, Wood JM, McSheehy PM et al. MTOR inhibitor RAD001 (Everolimus) has antiangio-genic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-22.
  24. Bachelot Th, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors. A GINECO Study. J Clin Oncol 2012; 30 (22): 2718-24.
  25. Beck TJ, Rugo HS, Howard A et al. BOLERO-2: health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane vs exemestane. Abstr. ASCO 2012.
  26. Piccart M, Baselga J, Noguchi S et al. Poster P6-04-02 final progression-free survival analysis of BOLERO-2. A phase III trial of everolimus for postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Sympos 2012; 4-8.
  27. Rugo HS, Pritchard KI, Gnant M et al. Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to Letrozole or Anastrozole: long-term efficacy and safety results of the BOLERO-2 trial. Abstr. 253. 8th European Breast Cancer Conference. Vienna, Austria 2012.
  28. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus Letrozole compared with placebo plus Letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27 (16): 2630-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964 от 18.12.2015 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies